Moderna cuts Covid vaccine sales forecast
Moderna cut its forecast for Covid-19 vaccine sales this year, citing delays in deliveries linked to supply chain constraints. The US biotech said on Thursday it expected vaccine sales to generate revenues of $18bn-$19bn in 2022, down from a forecast in August of $21bn. This reflects deferrals of orders worth between $2bn-$3bn into 2023, according…
Read more